2/9
07:00 am
iinn
Inspira Secures Vendor Approval from $12 Billion Revenue HMO (World’s 2nd Largest), Enabling Immediate ART100 Deployment
High
Report
Inspira Secures Vendor Approval from $12 Billion Revenue HMO (World’s 2nd Largest), Enabling Immediate ART100 Deployment
2/5
08:00 am
iinn
Inspira Announces Pricing of $4.75 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market under Nasdaq Rules
Medium
Report
Inspira Announces Pricing of $4.75 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market under Nasdaq Rules
2/3
09:22 am
iinn
Inspira Technologies Validates Next-Gen Standalone HYLA™ Blood Sensor with Clinical-Grade Accuracy, Targeting $48 Billion Heart-Lung Surgery Market
Low
Report
Inspira Technologies Validates Next-Gen Standalone HYLA™ Blood Sensor with Clinical-Grade Accuracy, Targeting $48 Billion Heart-Lung Surgery Market
1/29
08:30 am
iinn
ART100 Becomes Inspira’s First System to Complete Clinical Evaluation and Enters Budgeted Procurement at Top U.S. Medical Center
Low
Report
ART100 Becomes Inspira’s First System to Complete Clinical Evaluation and Enters Budgeted Procurement at Top U.S. Medical Center
1/21
08:50 am
iinn
Inspira Advances to Final Governmental Budgetary Validation Procedures for Previously Announced Binding Purchase Orders
Low
Report
Inspira Advances to Final Governmental Budgetary Validation Procedures for Previously Announced Binding Purchase Orders
1/8
08:50 am
iinn
Inspira Outlines Strategic Vision and Transaction Framework for Breast Cancer Liquid Biopsy Expansion
Medium
Report
Inspira Outlines Strategic Vision and Transaction Framework for Breast Cancer Liquid Biopsy Expansion
1/5
10:46 am
iinn
CORRECTION – Inspira Signs Term Sheet for Acquisition of Advanced Liquid Biopsy Cancer Diagnostics Technology and Investment of $15 Million into Inspira at $180 Million Valuation
Low
Report
CORRECTION – Inspira Signs Term Sheet for Acquisition of Advanced Liquid Biopsy Cancer Diagnostics Technology and Investment of $15 Million into Inspira at $180 Million Valuation
1/5
09:30 am
iinn
Inspira Signs Term Sheet for Acquisition of Advanced Liquid Biopsy Cancer Diagnostics Technology and Concurrent $15 Million Investment at $180 Million Valuation
Medium
Report
Inspira Signs Term Sheet for Acquisition of Advanced Liquid Biopsy Cancer Diagnostics Technology and Concurrent $15 Million Investment at $180 Million Valuation
12/23
08:30 am
iinn
Inspira Technologies Reaffirms $49.5 Million in Binding Purchase Orders and Aligns Execution with 2026 Regulatory and Deployment Milestones
Medium
Report
Inspira Technologies Reaffirms $49.5 Million in Binding Purchase Orders and Aligns Execution with 2026 Regulatory and Deployment Milestones
12/16
04:37 pm
iinn
Inspira Technologies OXY B.H.N. (NASDAQ:IINN) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Medium
Report
Inspira Technologies OXY B.H.N. (NASDAQ:IINN) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
12/15
08:30 am
iinn
Inspira Announces $1.8 Million Registered Direct Offering Priced At-The-Market and Additional Equity Financing Agreement to Support Ongoing Commercial Execution
Medium
Report
Inspira Announces $1.8 Million Registered Direct Offering Priced At-The-Market and Additional Equity Financing Agreement to Support Ongoing Commercial Execution
12/9
08:05 am
iinn
Inspira Technologies Granted Patent in Japan for the INSPIRA™ ART System's Convertible Dual Lumen Cannula Device and Method of Use
Low
Report
Inspira Technologies Granted Patent in Japan for the INSPIRA™ ART System's Convertible Dual Lumen Cannula Device and Method of Use
12/3
08:43 am
iinn
Inspira Technologies Announces Strategic Leap in Lab Capabilities – Accelerating Next-Generation Diagnostics and Blood Technology
Medium
Report
Inspira Technologies Announces Strategic Leap in Lab Capabilities – Accelerating Next-Generation Diagnostics and Blood Technology
11/26
02:09 pm
iinn
Inspira Technologies OXY B.H.N. (NASDAQ:IINN) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Neutral
Report
Inspira Technologies OXY B.H.N. (NASDAQ:IINN) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
11/13
09:00 am
iinn
Inspira Completes Clinical Study for HYLA™ Blood Sensor - Ahead of Regulatory Submission
Medium
Report
Inspira Completes Clinical Study for HYLA™ Blood Sensor - Ahead of Regulatory Submission